Sangamo Therapeutics Inc Stock Research

Market Summary

USD1.12-0.02

Market Closed

-1.75%

SGMO Alerts

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)

SGMO Stock Price

SGMO RSI Chart

SGMO Valuation

Market Cap

186.8M

Price/Earnings (Trailing)

-1.47

Price/Sales (Trailing)

0.78

EV/EBITDA

1.09

Price/Free Cashflow

-0.72

SGMO Price/Sales (Trailing)

SGMO Profitability

EBT Margin

-172.37%

Return on Equity

-65.2%

Return on Assets

-34.19%

Free Cashflow Yield

-138.37%

SGMO Fundamentals

SGMO Revenue

Revenue (TTM)

241.0M

Revenue Y/Y

459.52%

Revenue Q/Q

480.08%

SGMO Earnings

Earnings (TTM)

-127.2M

Earnings Y/Y

148.05%

Earnings Q/Q

140.64%

Price Action

52 Week Range

1.126.42

(Low)(High)

Last 7 days

-21.7%

Last 30 days

-25.8%

Last 90 days

-62.2%

Trailing 12 Months

-69.3%

SGMO Financial Health

Current Ratio

2.69

SGMO Investor Care

Shares Dilution (1Y)

14.30%

Diluted EPS (TTM)

-0.83

Peers (Alternatives to Sangamo Therapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	117.9B	26.2B	-7.64%	-12.03%	14.89	4.5	-0.48%	38.34%
GILD	96.0B	27.0B	-5.50%	23.66%	17.2	3.55	-1.56%	23.65%
MRNA	49.0B	15.1B	-4.27%	-12.12%	10.25	3.26	-33.37%	-67.32%
BIIB	42.8B	10.1B	-4.73%	48.21%	13.67	4.24	-6.61%	115.98%
MID-CAP
NBIX	8.7B	1.6B	-13.93%	-4.24%	136.39	5.46	32.38%	-10.36%
DNLI	4.1B	-	17.13%	24.41%	-11.15	38.1	122.90%	-29.67%
BEAM	2.4B	76.7M	3.81%	-9.32%	-7.51	30.96	41.73%	-32.75%
BBIO	2.2B	107.9M	-4.32%	100.88%	-4.54	20.39	54.84%	17.36%
SMALL-CAP
RCUS	1.5B	119.0M	11.39%	8.39%	-5.38	12.62	-69.61%	-584.39%
REPL	1.1B	10.0M	8.51%	30.70%	-6.18	107.56	215.65%	-47.65%
NVAX	694.6M	-	4.27%	-85.45%	-0.6	0.35	72.89%	12.32%
FATE	495.9M	136.9M	-20.60%	-78.14%	-2.11	3.62	116.83%	-0.93%
SGMO	186.8M	241.0M	-25.83%	-69.32%	-1.47	0.78	113.96%	27.87%
VXRT	165.4M	697.0K	50.34%	-66.48%	-1.53	237.34	47.98%	-35.48%
IBIO	8.7M	-	-35.78%	-88.38%	-0.11	3.21	0.51%	-129.47%

Financials for Sangamo Therapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	116.6%	241,025,000	111,299,000	112,055,000	114,158,000	112,652,000
Operating Expenses	21.3%	379,011,000	312,580,000	297,843,000	293,488,000	294,948,000
S&GA Expenses	5.1%	65,910,000	62,682,000	62,323,000	60,586,000	61,979,000
R&D Expenses	1.9%	254,530,000	249,898,000	235,520,000	232,902,000	232,969,000
EBITDA	-7.6%	-179,741,000	-166,995,000	-167,634,000	-	-
EBITDA Margin	-10.4%	-1.61	-1.46	-1.49	-	-
Earnings Before Taxes	144.5%	85,308,000	-191,849,000	-175,676,000	-	-
EBT Margin	-10.6%	-1.72	-1.56	-1.58	-	-
Net Income	33.9%	-127,190,000	-192,300,000	-177,790,000	-172,323,000	-176,324,000
Net Income Margin	-8.9%	-1.73	-1.59	-1.51	-1.57	-
Free Cahsflow	-3.8%	-243,798,000	-234,847,000	-241,443,000	-241,843,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-21.7%	441	563	594	617	654
Current Assets	-24.4%	227	300	337	343	340
Cash Equivalents	-20.6%	80.00	100	95.00	118	120
Net PPE	-5.8%	60.00	64.00	56.00	53.00	52.00
Goodwill	-100.0%	-	38.00	35.00	37.00	39.00
Liabilities	-60.8%	105	268	285	299	320
Current Liabilities	-48.2%	58.00	112	122	120	119
Shareholder's Equity	13.8%	336	295	309	318	335
Retained Earnings	1.8%	-1,127	-1,148	-1,096	-1,043	-1,000
Additional Paid-In Capital	1.2%	1,467	1,450	1,423	1,373	1,340
Shares Outstanding	5.5%	167	158	148	146	-

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-3.3%	-230	-223	-219	-225	-223
Share Based Compensation	1.9%	32.00	32.00	31.00	32.00	33.00
Cashflow From Investing	57.4%	93.00	59.00	69.00	144	205
Cashflow From Financing	11.3%	94.00	85.00	67.00	29.00	16.00

Risks for SGMO

What is the probability of a big loss on SGMO?

100%

Probability that Sangamo Therapeutics stock will be more than 20% underwater in next one year

95%

Probability that Sangamo Therapeutics stock will be more than 30% underwater in next one year.

85.8%

Probability that Sangamo Therapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SGMO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Sangamo Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for SGMO

Cumulative Returns on SGMO

-17.8%

10-Year Cumulative Returns

-22.9%

7-Year Cumulative Returns

-41.7%

5-Year Cumulative Returns

-53.6%

3-Year Cumulative Returns

What are the long-term rolling returns for SGMO?

FIve years rolling returns for Sangamo Therapeutics.

Annualized Returns

Which funds bought or sold SGMO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-26	ProShare Advisors LLC	reduced	-10.86	-48,345	48,279	-%
2023-05-22	AMERIPRISE FINANCIAL INC	reduced	-61.73	-170,471	46,529	-%
2023-05-19	Coppell Advisory Solutions LLC	sold off	-100	-628	-	-%
2023-05-18	JPMORGAN CHASE & CO	added	0.76	-2,133,720	2,771,280	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-49.84	-182,000	71,000	-%
2023-05-17	VIRGINIA RETIREMENT SYSTEMS ET AL	added	9.31	-72,500	169,560	-%
2023-05-17	Long Focus Capital Management, LLC	unchanged	-	-1,479,360	1,886,720	0.11%
2023-05-17	Advisory Services Network, LLC	unchanged	-	-276	352	-%
2023-05-16	Rockefeller Capital Management L.P.	sold off	-100	-1,000	-	-%
2023-05-16	Hudson Bay Capital Management LP	added	96.53	369,136	4,004,000	0.02%

Latest Funds Activity

Are funds buying SGMO calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own SGMO

No. of Funds

Sangamo Therapeutics News

Schedule 13G FIlings of Sangamo Therapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	wasatch advisors inc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.57%	14,045,609	SC 13G/A
Feb 07, 2023	state street corp	5.97%	9,788,884	SC 13G/A
Jan 24, 2023	blackrock inc.	9.4%	15,359,441	SC 13G/A
Feb 11, 2022	wasatch advisors inc	-	0	SC 13G/A
Feb 01, 2022	blackrock inc.	8.0%	11,662,880	SC 13G/A
Feb 11, 2021	wasatch advisors inc	-	0	SC 13G/A
Feb 10, 2021	vanguard group inc	5.98%	8,453,658	SC 13G/A
Feb 04, 2021	wellington management group llp	0.00%	229	SC 13G/A
Feb 01, 2021	blackrock inc.	6.8%	9,566,415	SC 13G/A

SGMO Fair Value

Show Fair-Value

Recent SEC filings of Sangamo Therapeutics

View All Filings

Date Filed	Form Type	Document
May 30, 2023	4	Insider Trading
May 30, 2023	4	Insider Trading
May 30, 2023	4	Insider Trading
May 30, 2023	4	Insider Trading
May 30, 2023	4	Insider Trading
May 30, 2023	4	Insider Trading
May 30, 2023	4	Insider Trading
May 08, 2023	10-Q	Quarterly Report
Apr 26, 2023	4	Insider Trading
Apr 26, 2023	8-K	Current Report

Latest Insider Trading transactions for SGMO

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-25	Willoughby Scott B.	sold (taxes)	-1,766	1.33	-1,328	svp, gen. counsel & secretary
2023-05-25	Fontenot Jason D.	sold (taxes)	-1,368	1.33	-1,029	svp, chief scientific officer
2023-05-25	Ramelmeier Rolf Andrew	sold (taxes)	-2,327	1.33	-1,750	evp, technical operations
2023-05-25	Macrae Sandy	sold (taxes)	-13,846	1.33	-10,411	president, ceo and director
2023-05-25	Dubois-Stringfellow Nathalie	sold (taxes)	-1,944	1.33	-1,462	svp-chief development officer
2023-05-25	McClung David Mark	sold (taxes)	-2,560	1.33	-1,925	evp, chief operating officer
2023-05-25	Duraibabu Prathyusha	sold (taxes)	-1,766	1.33	-1,328	svp, chief financial officer
2023-04-24	Willoughby Scott B.	sold (taxes)	-6,562	1.65	-3,977	svp, gen. counsel & secretary
2023-03-25	Duraibabu Prathyusha	sold (taxes)	-572	1.66	-345	svp, chief financial officer
2023-02-25	Dubois-Stringfellow Nathalie	sold (taxes)	-26,158	2.66	-9,834	svp-chief development officer

About Sangamo Therapeutics

Alexander D. Macrae

www.sangamo.com

430

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

SGMO Income Statement

2023-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Revenues	$ 157,957	$ 28,231
Operating expenses:
Research and development	63,216	58,584
General and administrative	18,136	14,908
Impairment of goodwill	38,138	0
Impairment of long-lived assets	20,433	0
Total operating expenses	139,923	73,492
Income (loss) from operations	18,034	(45,261)
Interest and other income, net	3,293	1,342
Income (loss) before income taxes	21,327	(43,919)
Income tax expense	194	58
Net income (loss)	$ 21,133	$ (43,977)
Net income (loss) per share
Basic (in dollars per share)	$ 0.13	$ (0.30)
Diluted (in dollars per share)	$ 0.12	$ (0.30)
Shares used in computing net income (loss) per share
Basic (in shares)	168,533	146,218
Diluted (in shares)	169,181	146,218

SGMO Balance Sheet

2023-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 78,241	$ 100,444
Marketable securities	127,146	177,188
Interest receivable	1,023	794
Accounts receivable	7,026	3,678
Prepaid expenses and other current assets	13,651	18,223
Total current assets	227,087	300,327
Marketable securities, non-current	35,610	29,845
Property and equipment, net	59,877	63,531
Intangible assets	51,555	50,729
Goodwill	0	37,552
Operating lease right-of-use assets	48,696	62,002
Other non-current assets	16,242	17,023
Restricted cash	1,500	1,500
Total assets	440,567	562,509
Current liabilities:
Accounts payable	19,920	22,418
Accrued compensation and employee benefits	12,949	21,506
Other accrued liabilities	15,395	16,007
Deferred revenues	9,575	51,780
Total current liabilities	57,839	111,711
Deferred revenues, non-current	1,816	109,377
Long-term portion of lease liabilities	37,701	38,986
Deferred income tax	6,372	6,270
Other non-current liabilities	1,229	1,207
Total liabilities	104,957	267,551
Commitments and contingencies
Stockholders’ equity:
Preferred stock	0	0
Common stock	1,718	1,668
Additional paid-in capital	1,467,062	1,450,239
Accumulated deficit	(1,127,412)	(1,148,545)
Accumulated other comprehensive loss	(5,758)	(8,404)
Total stockholders’ equity	335,610	294,958
Total liabilities and stockholders’ equity	$ 440,567	$ 562,509